Denali Capital shareholders approve extension to Apr 2025; 3.8M shares redeemed for ~$43.4M

Semnur Pharmaceuticals, Inc.

Shareholders approved extension of business combination deadline from July 11, 2024 to April 11, 2025 via monthly extensions.
3,785,992 public shares redeemed at ~$11.47 per share, removing ~$43.4 million from trust account; only 751,837 public shares remain.
Sponsor issued a convertible promissory note of up to $180,000 to fund extension deposits; initial $15,063.74 deposited for one-month extension.
Note is convertible into Class A ordinary shares at $10.00 per share upon business combination; no interest accrues.

item 1.01 item 2.03 item 5.03 item 5.07 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.